Work

A phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.4119

Authors: Daniel H. Palmer, Svein Dueland, Juan W. Valle, Anne-Kirsti Aksnes

Institutions: University of Liverpool, Oslo University Hospital, The Christie NHS Foundation Trust, Targovax (Norway)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889639085

Cites:

Cited by: 13

Related to: 10